Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy · Delayed Price · Currency is EUR 51.20
+0.60 (1.19%)
Sep 29, 2025, 9:43 AM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Specialty & Primary Care | 1.51B | Log In | Log In | Log In | Log In | Upgrade |
Specialty & Primary Care Growth | 5.18% | Log In | Log In | Log In | Log In | Upgrade |
Rare Diseases | 833.86M | Log In | Log In | Log In | Log In | Upgrade |
Rare Diseases Growth | 23.48% | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceutical Chemicals | 58.47M | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceutical Chemicals Growth | 10.99% | Log In | Log In | Log In | Log In | Upgrade |
Other | 2.28B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 11.53% | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular | 385.21M | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular Growth | 7.86% | Log In | Log In | Log In | Log In | Upgrade |
Urology and Uro-Oncology | 399.94M | Log In | Log In | Log In | Log In | Upgrade |
Urology and Uro-Oncology Growth | 13.21% | Log In | Log In | Log In | Log In | Upgrade |
Gastrointestinal | 217.50M | Log In | Log In | Log In | Log In | Upgrade |
Gastrointestinal Growth | 2.46% | Log In | Log In | Log In | Log In | Upgrade |
Cough and Cold | 137.28M | Log In | Log In | Log In | Log In | Upgrade |
Cough and Cold Growth | -0.97% | Log In | Log In | Log In | Log In | Upgrade |
Other Treatment Areas | 309.31M | Log In | Log In | Log In | Log In | Upgrade |
Other Treatment Areas Growth | -3.48% | Log In | Log In | Log In | Log In | Upgrade |
Hema-Oncology | 253.23M | Log In | Log In | Log In | Log In | Upgrade |
Hema-Oncology Growth | 51.33% | Log In | Log In | Log In | Log In | Upgrade |
Endocrinology | 321.69M | Log In | Log In | Log In | Log In | Upgrade |
Endocrinology Growth | 21.92% | Log In | Log In | Log In | Log In | Upgrade |
Metabolic and Other Areas | 258.94M | Log In | Log In | Log In | Log In | Upgrade |
Metabolic and Other Areas Growth | 1.55% | Log In | Log In | Log In | Log In | Upgrade |
Zanidip | - | Log In | Log In | Log In | Log In | Upgrade |
Zanidip Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Zanipress | - | Log In | Log In | Log In | Log In | Upgrade |
Zanipress Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Urorec | - | Log In | Log In | Log In | Log In | Upgrade |
Urorec Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Livazo | - | Log In | Log In | Log In | Log In | Upgrade |
Livazo Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Drugs for Rare Diseases | - | Log In | Log In | Log In | Log In | Upgrade |
Drugs for Rare Diseases Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Seloken/Logimax | - | Log In | Log In | Log In | Log In | Upgrade |
Seloken/Logimax Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Corporate Products | - | Log In | Log In | Log In | Log In | Upgrade |
Other Corporate Products Growth | - | Log In | Log In | Log In | Log In | Upgrade |
OTC | - | Log In | Log In | Log In | Log In | Upgrade |
OTC Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Local Product Portfolios | - | Log In | Log In | Log In | Log In | Upgrade |
Local Product Portfolios Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Product | - | Log In | Log In | Log In | Log In | Upgrade |
Other Product Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Eligard | - | Log In | Log In | Log In | Log In | Upgrade |
Eligard Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 2.28B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 11.53% | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | 59.50M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -3.23% | Log In | Log In | Log In | Log In | Upgrade |
Specialty & Primary Care Operating Income | 426.73M | Log In | Log In | Log In | Log In | Upgrade |
Specialty & Primary Care Operating Income Growth | -2.92% | Log In | Log In | Log In | Log In | Upgrade |
Rare Diseases Operating Income | 212.13M | Log In | Log In | Log In | Log In | Upgrade |
Rare Diseases Operating Income Growth | 36.18% | Log In | Log In | Log In | Log In | Upgrade |
Other | 59.50M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -3.23% | Log In | Log In | Log In | Log In | Upgrade |
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Specialty & Primary Care EBITDA | 524.44M | Log In | Log In | Log In | Log In | Upgrade |
Specialty & Primary Care EBITDA Growth | 2.23% | Log In | Log In | Log In | Log In | Upgrade |
Rare Diseases EBITDA | 341.33M | Log In | Log In | Log In | Log In | Upgrade |
Rare Diseases EBITDA Growth | 26.19% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Italy | 336.26M | Log In | Log In | Log In | Log In | Upgrade |
Italy Growth | 1.11% | Log In | Log In | Log In | Log In | Upgrade |
International | 2.01B | Log In | Log In | Log In | Log In | Upgrade |
International Growth | 13.36% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 1.65B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Asia and Oceania | 156.01M | Log In | Log In | Log In | Log In | Upgrade |
Asia and Oceania Growth | - | Log In | Log In | Log In | Log In | Upgrade |
America | 477.46M | Log In | Log In | Log In | Log In | Upgrade |
America Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Africa | 58.03M | Log In | Log In | Log In | Log In | Upgrade |
Africa Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Specialty & Primary Care Like-For-Like Growth | 5.70% | Log In | Log In | Log In | Log In | Upgrade |
Rare Diseases Like-For-Like Growth | 15.70% | Log In | Log In | Log In | Log In | Upgrade |
Total Like-For-Like Growth | 9.20% | Log In | Log In | Log In | Log In | Upgrade |